(Reuters) - MEI Pharma was set to lose more than half its market value on Monday after the company's cancer drug failed to meet the main goal in a mid-stage study.
The drug, pracinostat, was being tested in combination with chemotherapy drug azacitidine to treat patients with myelodysplastic syndrome - a type of blood cancer.
19:30 Virgin Galactic spaceship makes first glide flight45
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff17
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle19
13:37 GoPro to cut about 15 percent of workforce14